儿童威尔逊病肝硬化的血液学预测因素:基于记录的分析
Sukru Gungor1, Fatma I Varol1, Yurday Öncül2
1Paediatric Gastroenterology, Hepatology and Nutrition, Inonu University, Malatya, TUR.
Cureus
|November 18, 2025
概括
像RDW和MCV这样的血液学参数可以预测威尔逊病 (WD) 患者的预后. 这些血液样本中的特定切断点有助于识别患有肝硬化风险较高的患者.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 血液学 血液学 血液学
- 临床诊断 临床诊断 临床诊断
背景情况:
- 威尔逊病 (WD) 是一种铜代谢的遗传性疾病.
- 早期诊断和管理对于预防严重肝损伤至关重要.
研究的目的:
- 调查威尔逊病患者常规血液学参数的预后价值.
- 为了确定特定的血液学标记和切断点,预测WD中肝硬化.
主要方法:
- 从2010年至2022年期间诊断的136名WD患者的实验室数据的回顾性分析.
- 根据肝硬化存在的基因病理学数据分组81名患者.
- 血液学参数与死亡率和肝硬化风险的相关性分析.
主要成果:
- 在Mentzer指数,RDW,MCV和死亡率得分之间发现了显著的相关性.
- Hb,红细胞,PLT和PCT显示与死亡率有负相关性.
- 确定了PLT,RDW和PCT的切线点,具有高灵敏度/特异性来预测肝硬化.
- 特定指数 (门策,PLT,MCV,RBC,PCT,RDW,Hb/RDW,AAR) 在定义的值时显著增加了肝硬化风险.
结论:
- 血液学参数为威尔逊病提供了宝贵的预后见解.
- 常规血液检查可以帮助临床医生评估WD患者的预后和肝硬化风险.
- 该研究强调了可访问的实验室数据在WD管理中的实用性.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
204
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
204
Pharmacokinetics in Pediatric Patients: Drug Metabolism
179
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
179
Pharmacokinetics in Pediatric Patients: Drug Distribution
247
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
247
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
232
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
232


